| 申兴勇,徐 昕,袁 平,喻召才,李新涛.参附注射液联合TEC新辅助化疗治疗乳腺癌的临床疗效及安全性分析[J].,2018,(23):4560-4563 |
| 参附注射液联合TEC新辅助化疗治疗乳腺癌的临床疗效及安全性分析 |
| Clinical Effect and Safety of Shenfu Injection Combined with TEC Neoadjuvant Chemotherapy on Breast Cancer |
| 投稿时间：2018-06-23 修订日期：2018-07-18 |
| DOI：10.13241/j.cnki.pmb.2018.23.038 |
| 中文关键词: 参附注射液 TEC方案 乳腺癌 骨髓抑制 |
| 英文关键词: Shenfu injection TEC solution Breast cancer Bone marrow suppression |
| 基金项目:国家自然科学基金项目(81372458) |
|
| 摘要点击次数: 569 |
| 全文下载次数: 286 |
| 中文摘要: |
| 摘要 目的：研究参附注射液联合TEC方案新辅助化疗治疗乳腺癌的临床疗效及安全性。方法：选取我院肿瘤科及乳腺外科2016年7月-2018年1月收治的120例乳腺癌患者，将其随机分为对照组和观察组。对照组50例给予TEC方案新辅助化疗；观察组70例给予TEC方案新辅助化疗联合参附注射液静脉滴注治疗。观察并比较两组患者治疗后的临床治疗效果，治疗前后白细胞、中性粒细胞、红细胞以及血小板计数、CD4+、CD8+和CD4+/CD8+的变化。结果：治疗后，对照组的总有效率为70%，观察组的总有效率为84.3%，观察组显著高于对照组(P<0.05)。两组治疗后白细胞、中性粒细胞、红细胞、血小板板计数、CD4+、CD8+和CD4+/CD8+均较治疗前有不同程度减少，对照组以上指标均明显低于观察组(P<0.05)。两组患者均发生口腔黏膜炎、呕吐、腹泻、便秘等不良反应，观察组不良反应发生率显著低于对照组(P<0.05)，且两组均未发生毒性反应致死事件。结论：TEC方案新辅助化疗联合参附注射液静脉滴注治疗乳腺癌患者能有效改善患者的细胞免疫功能，提高临床疗效，并且能有效抑制骨髓抑制和消化道反应，提高患者依从性。 |
| 英文摘要: |
| ABSTRACT Objective: To study the clinical efficacy and safety of Shenfu injection combined with TEC neoadjuvant chemotherapy in the treatment of breast cancer. Methods: 120 cases of breast cancer patients admitted in our hospital from July 2016 to January 2018 were randomly divided into the control group and the observation group. Among them, 50 patients in the control group were treated with TEC protocol neoadjuvant chemotherapy; 70 patients in the observation group were treated with TEC protocol neoadjuvant chemotherapy combined with Shenfu injection. The clinical treatment effects after treatment, changes of white blood cells, neutrophils, red blood cells and platelets, CD4+, CD8+ and CD4+/CD8+ before and after treatment were observed and compared between two groups. Results: After treatment, the total effective rate of control group was 70%, which was higher in the observation group (84.3%)(P<0.05), the white blood cells, neutrophils, erythrocytes, platelet counts, CD4+, CD8+, and CD4+/CD8+ levels of both groups were significnatly decreased than those before treatment. The above indicators in the control group were significantly lower than those in the observation group(P<0.05). Both groups of patients suffered from stomatitis, vomiting, diarrhea, constipation and other adverse reactions, but the incidence of adverse re- actions in the observation group was significantly lower than that of the control group(P<0.05), and no toxic reaction death occurred in both groups. Conclusion: TEC neoadjuvant chemotherapy combined with Shenfu Injection can effectively improve the cellular immune function, enhance the clinical efficacy, and reduce the myelosuppression and gastrointestinal reactions in the treatment of patients with breast cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
